CC vs SPXC
The Chemours Company vs SPX Technologies — AI-powered side-by-side comparison
CC
The Chemours Company
44
Reduce
VS
SPXC
SPX Technologies
71
Buy
| Metric | CC | SPXC |
|---|
| AI Score |
44
|
71
|
| Price |
$14.81
|
$216.94
|
| P/E Ratio |
-7.40×
|
38.51×
|
| ROE |
-154.4%
|
10.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
15.3%
|
40.2%
|
| Debt / Equity |
-82.92×
|
0.26×
|
| Dividend Yield |
2.4%
|
0.0%
|
| RSI (14) |
36.7
|
48.0
|
| Beta |
1.428
|
1.289
|
| Expected Upside |
—
|
+6.2%
|
AI Committee View
Current Innellis committee reasoning for CC versus SPXC.
SPXC leads by 27 points.
SPXC scores 71/100 (Buy) versus CC at 44/100 (Reduce).
CC Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -1.4% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- Beta of 1.37 means this name should amplify a favorable market regime — Macro
Bear Case
- Price-to-book of 7.1x prices in significant intangible value — Value
- ROE of only -164.4% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 16.56 adds balance-sheet risk to the value case — Value
SPXC Committee View
75% agreement
4 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Risk/reward is unfavorable: 9.6% downside vs 6.2% upside.